Cargando…

Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review

Radiation therapy (RT) is the standard of care in patients with locoregional or isolated vaginal recurrence who never underwent irradiation. It is often associated with brachytherapy (BT), whereas chemotherapy (CT) is a rare treatment option. We systematically searched the PubMed and Scopus database...

Descripción completa

Detalles Bibliográficos
Autores principales: Ronsini, Carlo, Iavarone, Irene, Reino, Antonella, Vastarella, Maria Giovanna, De Franciscis, Pasquale, Sangiovanni, Angelo, Della Corte, Luigi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304022/
https://www.ncbi.nlm.nih.gov/pubmed/37373875
http://dx.doi.org/10.3390/jpm13060886
_version_ 1785065410495774720
author Ronsini, Carlo
Iavarone, Irene
Reino, Antonella
Vastarella, Maria Giovanna
De Franciscis, Pasquale
Sangiovanni, Angelo
Della Corte, Luigi
author_facet Ronsini, Carlo
Iavarone, Irene
Reino, Antonella
Vastarella, Maria Giovanna
De Franciscis, Pasquale
Sangiovanni, Angelo
Della Corte, Luigi
author_sort Ronsini, Carlo
collection PubMed
description Radiation therapy (RT) is the standard of care in patients with locoregional or isolated vaginal recurrence who never underwent irradiation. It is often associated with brachytherapy (BT), whereas chemotherapy (CT) is a rare treatment option. We systematically searched the PubMed and Scopus databases in February 2023. We included patients with relapsed endometrial cancer, describing the treatment of locoregional recurrence, and reporting at least one outcome of interest—disease-free survival (DFS), overall survival (OS), recurrence rate (RR), site of recurrence, and major complications. A total of 15 studies fulfilled the inclusion criteria. Overall, 11 evaluated RT only, 3 evaluated CT, and 1 analyzed oncological outcomes after administration with a combination of CT and RT. In total, 4.5-year OS ranged from 16% to 96%, and DFS ranged from 36.3% to 100% at 4.5 years. RR ranged from 3.7% to 98.2% during a median follow-up of 51.5 months. Overall, RT showed a 4.5-year DFS from 40% to 100%. CT revealed 36.3% DFS at 4.5 years. RT showed a 4.5-year OS ranging from 16% to 96%, whereas CT revealed a 27.7% OS rate. It would be appropriate to test multi-modality regimens to evaluate outcomes and toxicity. EBRT and BT are the most employed options to treat vaginal recurrences.
format Online
Article
Text
id pubmed-10304022
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103040222023-06-29 Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review Ronsini, Carlo Iavarone, Irene Reino, Antonella Vastarella, Maria Giovanna De Franciscis, Pasquale Sangiovanni, Angelo Della Corte, Luigi J Pers Med Systematic Review Radiation therapy (RT) is the standard of care in patients with locoregional or isolated vaginal recurrence who never underwent irradiation. It is often associated with brachytherapy (BT), whereas chemotherapy (CT) is a rare treatment option. We systematically searched the PubMed and Scopus databases in February 2023. We included patients with relapsed endometrial cancer, describing the treatment of locoregional recurrence, and reporting at least one outcome of interest—disease-free survival (DFS), overall survival (OS), recurrence rate (RR), site of recurrence, and major complications. A total of 15 studies fulfilled the inclusion criteria. Overall, 11 evaluated RT only, 3 evaluated CT, and 1 analyzed oncological outcomes after administration with a combination of CT and RT. In total, 4.5-year OS ranged from 16% to 96%, and DFS ranged from 36.3% to 100% at 4.5 years. RR ranged from 3.7% to 98.2% during a median follow-up of 51.5 months. Overall, RT showed a 4.5-year DFS from 40% to 100%. CT revealed 36.3% DFS at 4.5 years. RT showed a 4.5-year OS ranging from 16% to 96%, whereas CT revealed a 27.7% OS rate. It would be appropriate to test multi-modality regimens to evaluate outcomes and toxicity. EBRT and BT are the most employed options to treat vaginal recurrences. MDPI 2023-05-24 /pmc/articles/PMC10304022/ /pubmed/37373875 http://dx.doi.org/10.3390/jpm13060886 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Ronsini, Carlo
Iavarone, Irene
Reino, Antonella
Vastarella, Maria Giovanna
De Franciscis, Pasquale
Sangiovanni, Angelo
Della Corte, Luigi
Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review
title Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review
title_full Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review
title_fullStr Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review
title_full_unstemmed Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review
title_short Radiotherapy and Chemotherapy Features in the Treatment for Locoregional Recurrence of Endometrial Cancer: A Systematic Review
title_sort radiotherapy and chemotherapy features in the treatment for locoregional recurrence of endometrial cancer: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10304022/
https://www.ncbi.nlm.nih.gov/pubmed/37373875
http://dx.doi.org/10.3390/jpm13060886
work_keys_str_mv AT ronsinicarlo radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview
AT iavaroneirene radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview
AT reinoantonella radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview
AT vastarellamariagiovanna radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview
AT defranciscispasquale radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview
AT sangiovanniangelo radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview
AT dellacorteluigi radiotherapyandchemotherapyfeaturesinthetreatmentforlocoregionalrecurrenceofendometrialcancerasystematicreview